FDA panel offers unanimous endorsement of Theratech’s HIV drug

Canada's Theratechnologies took a big step forward on Thursday, winning the unanimous backing of 16 FDA panel members who recommended its new HIV drug tesamorelin for approval. Designed to treat the excess build-up of abdominal fat, the fate of tesamorelin now moves to the agency, which has set a July 27 deadline for a final decision. The FDA isn't bound by the recommendation, but the agency is unlikely to ignore a unanimous vote in its favor. "The advisory committee's recommendation is...